Elizabeth R Bertone-Johnson1, JoAnn E Manson2,3,4, Alexandra C Purdue-Smithe1, Susan E Hankinson1,2,3, Bernard A Rosner2,5, Brian W Whitcomb1. 1. Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, MA. 2. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 3. Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA. 4. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. 5. Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA.
Abstract
OBJECTIVE: Early menopause, the cessation of ovarian function before age 45, has consequences for fertility and cardiovascular health. Evidence from studies of women with autoimmune conditions and genetic studies supports a role for inflammation in early menopause, but the association of inflammatory markers and risk has not been directly evaluated. METHODS: We assessed the relation of the soluble fraction of tumor necrosis factor alpha receptor 2 (sTNFR2), C-reactive protein, interleukin-6 (IL6) levels with incident early menopause among Nurses' Health Study II participants who provided a premenopausal blood sample in 1996 to 1999. Cases (n = 328) were women reporting natural menopause between blood collection and age 45.Controls (n = 492) included (1) 328 women with menopause after age 47, matched 1:1 with cases on age at blood collection and other factors; and (2) 164 additional women with menopause after age 45. RESULTS: In multivariable models comparing cases and n = 492 controls, we observed a significant association of sTNFR2 levels and risk of early menopause (P = 0.002). Compared with women with the lowest sTNFR2 levels, odds ratios (95% CIs) for quartiles 2 to 4 were 0.60 (0.38-0.95), 0.93 (0.61-1.43), and 1.40 (0.93-2.11). Results further adjusting for antimüllerian hormone levels were similar in magnitude, as were results from sensitivity analyses of matched cases and controls (n = 328 pairs), nonsmokers, and leaner women. C-reactive protein and IL6 levels were unrelated to risk. CONCLUSIONS: The observation of lower risk of early menopause among women with moderate sTNFR2 levels compared with women with lower and higher levels warrants further prospective study.
OBJECTIVE: Early menopause, the cessation of ovarian function before age 45, has consequences for fertility and cardiovascular health. Evidence from studies of women with autoimmune conditions and genetic studies supports a role for inflammation in early menopause, but the association of inflammatory markers and risk has not been directly evaluated. METHODS: We assessed the relation of the soluble fraction of tumor necrosis factor alpha receptor 2 (sTNFR2), C-reactive protein, interleukin-6 (IL6) levels with incident early menopause among Nurses' Health Study II participants who provided a premenopausal blood sample in 1996 to 1999. Cases (n = 328) were women reporting natural menopause between blood collection and age 45.Controls (n = 492) included (1) 328 women with menopause after age 47, matched 1:1 with cases on age at blood collection and other factors; and (2) 164 additional women with menopause after age 45. RESULTS: In multivariable models comparing cases and n = 492 controls, we observed a significant association of sTNFR2 levels and risk of early menopause (P = 0.002). Compared with women with the lowest sTNFR2 levels, odds ratios (95% CIs) for quartiles 2 to 4 were 0.60 (0.38-0.95), 0.93 (0.61-1.43), and 1.40 (0.93-2.11). Results further adjusting for antimüllerian hormone levels were similar in magnitude, as were results from sensitivity analyses of matched cases and controls (n = 328 pairs), nonsmokers, and leaner women. C-reactive protein and IL6 levels were unrelated to risk. CONCLUSIONS: The observation of lower risk of early menopause among women with moderate sTNFR2 levels compared with women with lower and higher levels warrants further prospective study.
Authors: Lynne T Shuster; Deborah J Rhodes; Bobbie S Gostout; Brandon R Grossardt; Walter A Rocca Journal: Maturitas Date: 2009-09-05 Impact factor: 4.342
Authors: Jennifer K Pai; Tobias Pischon; Jing Ma; JoAnn E Manson; Susan E Hankinson; Kaumudi Joshipura; Gary C Curhan; Nader Rifai; Carolyn C Cannuscio; Meir J Stampfer; Eric B Rimm Journal: N Engl J Med Date: 2004-12-16 Impact factor: 91.245
Authors: Brian W Whitcomb; Sunni L Mumford; Neil J Perkins; Jean Wactawski-Wende; Elizabeth R Bertone-Johnson; Kristine E Lynch; Enrique F Schisterman Journal: Fertil Steril Date: 2014-02-26 Impact factor: 7.329
Authors: Elizabeth M Poole; I-Min Lee; Paul M Ridker; Julie E Buring; Susan E Hankinson; Shelley S Tworoger Journal: Am J Epidemiol Date: 2013-08-21 Impact factor: 4.897
Authors: G A Colditz; M J Stampfer; W C Willett; W B Stason; B Rosner; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1987-08 Impact factor: 4.897
Authors: Madhavi Thombre Kulkarni; Amy Shafrir; Leslie V Farland; Kathryn L Terry; Brian W Whitcomb; A Heather Eliassen; Elizabeth R Bertone-Johnson; Stacey A Missmer Journal: JAMA Netw Open Date: 2022-01-04